585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC) — Cora N. Sternberg (2021) | RDL Network
585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Zhen Shi, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Marie-Laurence Harle-Yge, Małgorzata Nowicka, Matthew Wongchenko, Johann S. de Bono
Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Rustem Gafanov, Francis Parnis, Gary L. Buchschacher, Luis Corrales, Michael Borre, Gustavo Vasconcelos Alves, Josep Garcia, M-L. Harle-Yge, G. Chen, Matthew Wongchenko, Christopher J. Sweeney, Johann S. de Bono, Sergio Bracarda, Cora N. Sternberg, K.N. Chi, David Olmos
Johann S. de Bono, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Josep Garcia, Małgorzata Nowicka, Matthew Wongchenko, Zhen Shi
Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, Fanny Schenkel, Rucha Sane, Healther Hinton, Sergio Bracarda, Cora N. Sternberg
Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge D. Gallo,
Discussion(0)
No comments yet. Be the first to comment.